HomeREGULATORY
REGULATORY

Chuikyo Ponders How to Deal with ICER for Products with Multiple Indications
(Sep.14.2017)

A subcommittee of the Central Social Insurance Medical Council, better known as Chuikyo, on September 13 discussed ways to handle the ICER (incremental cost-effectiveness ratio) for some of the 13 products under a pilot-based “cost-effective assessment (CEA)” program that have more than one indication, including Opdivo (nivolumab) ...
(LOG IN FOR FULL STORY)

News Calendar